ArticleFrontiers in pharmacology2021

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China.

Chen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.